Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Research & Development (2020 - 2025)

Ovid Therapeutics' Research & Development history spans 6 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Research & Development rose 11.24% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $25.6 million, down 30.4%, while the annual FY2025 figure was $25.6 million, 30.42% down from the prior year.
  • Research & Development reached $6.6 million in Q4 2025 per OVID's latest filing, up from $5.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $16.2 million in Q1 2021 to a low of $4.9 million in Q3 2021.
  • Average Research & Development over 5 years is $7.8 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: plummeted 69.02% in 2021, then soared 109.73% in 2024.
  • A 5-year view of Research & Development shows it stood at $12.3 million in 2021, then plummeted by 54.83% to $5.6 million in 2022, then surged by 91.53% to $10.6 million in 2023, then crashed by 44.34% to $5.9 million in 2024, then increased by 11.24% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Research & Development are $6.6 million (Q4 2025), $5.9 million (Q3 2025), and $6.5 million (Q2 2025).